GeorgiNutsov Australian biotechnology company Immutep ( NASDAQ: IMMP ) rose in premarket trading on Friday, after the company reported positive results in first line head and neck squamous cell carcinoma patients with negative PD-L1 expression. Immutep ( IMMP ) advanced +19.15% premarket to $2.
40. The updated efficacy and safety data was presented by Dr. Robert Metcalf during an oral presentation at the ESMO Virtual Plenary session at 18:30-19:30 CEST on 11 July 2024, Immutep ( IMMP ) said.
According to the company, the investigational immuno-oncology combination utilising efti and KEYTRUDA achieved an objective response rate of 35.5% (11 of 31 evaluable patients) and a disease control rate of 58.1%.
This new data adds to the body of evidence that efti’s novel activation of antigen-presenting cells provides a strong boost to the immune system, enhancing the potential of immune checkpoint inhibitors such as KEYTRUDA. Source: Press Release More on Immutep Immutep: Realizing The Expected Catalysts, With More To Come Immutep slips after stock offering Immutep reports promising efti/Keytruda data for head and neck cancer Seeking Alpha’s Quant Rating on Immutep Historical earnings data for Immutep.